Skip to main content


Log in

Strontium-89 (Sr-89) chloride in the treatment of various cancer patients with multiple bone metastases

  • Original Article
  • Published:
International Journal of Clinical Oncology Aims and scope Submit manuscript



Although the use of Sr-89 chloride in the treatment of patients with prostate and breast cancer has been widely reported, little information is available about its use for other malignancies. Here, we retrospectively analyzed the clinical profile of Sr-89 chloride in various patients with painful bone metastases.


Entry criteria were a pathologically proven malignancy, clinically diagnosed multiple bone metastases, and adequate organ function. Sr-89 chloride (Metastron) was given by single intravenous infusion at 2 MBq/kg over 2 min. Self-reported outcome measures were used as a response index, including pain diary data on a 0–10 numeric rating scale (NRS).


Fifty-four consecutive patients with painful bone metastases were treated with Sr-89 chloride at the National Cancer Center Hospital East between March 2009 and July 2011, consisting of 26 with breast/prostate cancer and 28 with other malignancies (lung 8, head and neck 6, colorectal 6, others 8). Thirteen (24 %) patients experienced a transient increase in pain, which was categorized as a flare-up response. Grade 3–4 anemia was observed in 6 patients, 3 of whom required blood transfusion. Regarding efficacy, response rates and complete response rates were 71.2 % and 34.6 %, respectively, and time to response from the initiation of treatment was 36 days (range, 13–217). No significant difference in response rates was seen between patients with breast/prostate cancer and other cancers (breast/prostate 69.2 %, other 73.1 %; p = 0.76).


As in patients with breast and prostate cancer, Sr-89 chloride is a promising agent for the treatment of painful bone metastases in patients with various other malignancies.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or Ebook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2

Similar content being viewed by others


  1. Paes FM, Serafini AN (2010) Systemic metabolic radiopharmaceutical therapy in the treatment of metastatic bone pain. Semin Nucl Med 40:89–104

    Article  PubMed  Google Scholar 

  2. Taylor AJ Jr (1994) Strontium-89 for the palliation of bone pain due to metastatic disease. J Nucl Med 35:2054

    Google Scholar 

  3. Lam MG, de Klerk JM, van Rijk PP et al (2007) Bone seeking radiopharmaceuticals for palliation of pain in cancer patients with osseous metastases. Anticancer Agents Med Chem 7:381–397

    Article  CAS  PubMed  Google Scholar 

  4. Blake GM, Zivanovic MA, Blaquiere RM et al (1988) Strontium-89 therapy: measurement of absorbed dose to skeletal metastases. J Nucl Med 29:549–557

    CAS  PubMed  Google Scholar 

  5. Fuster D, Herranz D, Vidal-Sicart S et al (2000) Usefulness of strontium-89 for bone pain palliation in metastatic breast cancer patients. Nucl Med Commun 21:623–626

    Article  CAS  PubMed  Google Scholar 

  6. Turner SL, Gruenewald S, Spry N et al (2001) Less pain does equal better quality of life following strontium-89 therapy for metastatic prostate cancer. Br J Cancer 84:297–302

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  7. Baczyk M, Milecki P, Baczyk E et al (2003) The effectivness of strontium-89 in palliative therapy of painful prostate cancer bone metastases. Ortop Traumatol Rehabil 5:364–368

    PubMed  Google Scholar 

  8. Ashayeri E, Omogbehin A, Sridhar R et al (2002) Strontium-89 in the treatment of pain due to diffuse osseous metastases: a university hospital experience. J Natl Med Assoc 94:706–711

    PubMed Central  PubMed  Google Scholar 

  9. Kraeber-Bodere F, Campion L, Rousseau C et al (2000) Treatment of bone metastases of prostate cancer with strontium-89 chloride: efficacy in relation to the degree of bone involvement. Eur J Nucl Med 27:1487–1493

    Article  CAS  PubMed  Google Scholar 

  10. Paice JA, Cohen FL (1997) Validity of a verbally administered numeric rating scale to measure cancer pain intensity. Cancer Nurs 20:88–93

    Article  CAS  PubMed  Google Scholar 

  11. Williamson A, Hoggart B (2005) Pain: a review of three commonly used pain rating scales. J Clin Nurs 14:798–804

    Article  PubMed  Google Scholar 

  12. Gunawardana DH, Lichtenstein M, Better N et al (2004) Results of strontium-89 therapy in patients with prostate cancer resistant to chemotherapy. Clin Nucl Med 29:81–85

    Article  PubMed  Google Scholar 

  13. Smeland S, Erikstein B, Aas M et al (2003) Role of strontium-89 as adjuvant to palliative external beam radiotherapy is questionable: results of a double-blind randomized study. Int J Radiat Oncol Biol Phys 56:1397–1404

    Article  PubMed  Google Scholar 

  14. Windsor PM (2001) Predictors of response to strontium-89 (Metastron) in skeletal metastases from prostate cancer: report of a single centre’s 10-year experience. Clin Oncol (R Coll Radiol) 13:219–227

    CAS  Google Scholar 

  15. Laing AH, Ackery DM, Bayly RJ et al (1991) Strontium-89 chloride for pain palliation in prostatic skeletal malignancy. Br J Radiol 64:816–822

    Article  CAS  PubMed  Google Scholar 

  16. Schmeler K, Bastin K (1996) Strontium-89 for symptomatic metastatic prostate cancer to bone: recommendations for hospice patients. Hosp J 11:1–10

    CAS  PubMed  Google Scholar 

  17. Firusian N (1978) Endo-osseous isotope therapy of malignant skeletal disease (author’s translation). Z Krebsforsch Klin Onkol Cancer Res Clin Oncol 91:143–156

    Article  CAS  PubMed  Google Scholar 

  18. Silberstein EB, Williams C (1985) Strontium-89 therapy for the pain of osseous metastases. J Nucl Med 26:345–348

    CAS  PubMed  Google Scholar 

Download references


This study was supported by a Ministry of Education, Culture, Sports, Science and Technology scientific research grant.

Conflict of interest

We have no conflict of interest.

Ethical standard

In the present study, written informed consent for treatment was obtained from all patients before the initiation of treatment. This study was approved in Institutional Review Board of National Cancer Center Hospital, Japan.

Author information

Authors and Affiliations


Corresponding author

Correspondence to Sadamoto Zenda.

About this article

Cite this article

Zenda, S., Nakagami, Y., Toshima, M. et al. Strontium-89 (Sr-89) chloride in the treatment of various cancer patients with multiple bone metastases. Int J Clin Oncol 19, 739–743 (2014).

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: